Outcomes after Allogeneic Transplant in Patients with Wiskott-Aldrich Syndrome

Alexander Ngwube, I. Celine Hanson, Jordan Orange, Nicholas L. Rider, Filiz Seeborg, William Shearer, Lenora Noroski, Sarah Nicholas, Lisa Forbes, Kathryn Leung, Ghadir Sasa, Swati Naik, Meenakshi Hegde, Bilal Omer, Nabil Ahmed, Carl Allen, Stephen Gottschalk, Meng Fen Wu, Hao Liu, Malcolm Brenner & 3 others Helen Heslop, Robert Krance, Caridad Martinez

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Wiskott-Aldrich syndrome (WAS) is a rare X-linked disorder characterized by a triad of immunodeficiency, eczema, and thrombocytopenia. Currently, hematopoietic stem cell transplantation (HSCT) is the most reliable curative treatment with excellent results for patients with HLA-matched family or unrelated donors. However, even after fully myeloablative preparative regimens, mixed donor chimerism is a potential concern. We performed a retrospective chart review of 12 children who underwent allogeneic HSCT for WAS to report our experience. The median age at transplant was 10.5 months (range, 3 to 39). The median nucleated cell dose from the marrow was 4.55 × 10 9 /kg (range,.3 to 7.9). The median times to neutrophil and platelet engraftment were 19 days (range, 13 to 27) and 18.5 days (range, 12 to 31), respectively. The rate of overall survival was 92% with median follow-up of 67 months (range, 3 to 146). Two patients developed grade IV acute graft-versus-host disease, and 1 died on day +99. Five of 12 patient's (42%) had mixed donor chimerism (range, 12% to 85%) at day +180. None of the pretransplant patient parameters was predictive of mixed chimerism. Nonetheless, of these 5 patients, 2 had normalization of the platelet count despite the mixed chimerism, 2 had full donor chimerism after receiving a second transplant with the same donor, and 1 remains transfusion dependent awaiting a second transplant. Hence, even with a significant rate of mixed chimerism, HSCT provides substantial benefit to WAS patients, with excellent overall survival.

Original languageEnglish (US)
Pages (from-to)537-541
Number of pages5
JournalBiology of Blood and Marrow Transplantation
Volume24
Issue number3
DOIs
StatePublished - Mar 1 2018
Externally publishedYes

Fingerprint

Wiskott-Aldrich Syndrome
Chimerism
Transplants
Hematopoietic Stem Cell Transplantation
Tissue Donors
Unrelated Donors
Eczema
Graft vs Host Disease
Platelet Count
Thrombocytopenia
Neutrophils
Blood Platelets
Survival Rate
Bone Marrow
Survival

Keywords

  • Hematopoietic cell transplant
  • Mixed chimerism
  • Primary immunodeficiency
  • Wiskott-Aldrich syndrome

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Ngwube, A., Hanson, I. C., Orange, J., Rider, N. L., Seeborg, F., Shearer, W., ... Martinez, C. (2018). Outcomes after Allogeneic Transplant in Patients with Wiskott-Aldrich Syndrome. Biology of Blood and Marrow Transplantation, 24(3), 537-541. https://doi.org/10.1016/j.bbmt.2017.11.019

Outcomes after Allogeneic Transplant in Patients with Wiskott-Aldrich Syndrome. / Ngwube, Alexander; Hanson, I. Celine; Orange, Jordan; Rider, Nicholas L.; Seeborg, Filiz; Shearer, William; Noroski, Lenora; Nicholas, Sarah; Forbes, Lisa; Leung, Kathryn; Sasa, Ghadir; Naik, Swati; Hegde, Meenakshi; Omer, Bilal; Ahmed, Nabil; Allen, Carl; Gottschalk, Stephen; Wu, Meng Fen; Liu, Hao; Brenner, Malcolm; Heslop, Helen; Krance, Robert; Martinez, Caridad.

In: Biology of Blood and Marrow Transplantation, Vol. 24, No. 3, 01.03.2018, p. 537-541.

Research output: Contribution to journalArticle

Ngwube, A, Hanson, IC, Orange, J, Rider, NL, Seeborg, F, Shearer, W, Noroski, L, Nicholas, S, Forbes, L, Leung, K, Sasa, G, Naik, S, Hegde, M, Omer, B, Ahmed, N, Allen, C, Gottschalk, S, Wu, MF, Liu, H, Brenner, M, Heslop, H, Krance, R & Martinez, C 2018, 'Outcomes after Allogeneic Transplant in Patients with Wiskott-Aldrich Syndrome', Biology of Blood and Marrow Transplantation, vol. 24, no. 3, pp. 537-541. https://doi.org/10.1016/j.bbmt.2017.11.019
Ngwube, Alexander ; Hanson, I. Celine ; Orange, Jordan ; Rider, Nicholas L. ; Seeborg, Filiz ; Shearer, William ; Noroski, Lenora ; Nicholas, Sarah ; Forbes, Lisa ; Leung, Kathryn ; Sasa, Ghadir ; Naik, Swati ; Hegde, Meenakshi ; Omer, Bilal ; Ahmed, Nabil ; Allen, Carl ; Gottschalk, Stephen ; Wu, Meng Fen ; Liu, Hao ; Brenner, Malcolm ; Heslop, Helen ; Krance, Robert ; Martinez, Caridad. / Outcomes after Allogeneic Transplant in Patients with Wiskott-Aldrich Syndrome. In: Biology of Blood and Marrow Transplantation. 2018 ; Vol. 24, No. 3. pp. 537-541.
@article{0ec16b51ca67440fa4fcd1e8b295ec78,
title = "Outcomes after Allogeneic Transplant in Patients with Wiskott-Aldrich Syndrome",
abstract = "Wiskott-Aldrich syndrome (WAS) is a rare X-linked disorder characterized by a triad of immunodeficiency, eczema, and thrombocytopenia. Currently, hematopoietic stem cell transplantation (HSCT) is the most reliable curative treatment with excellent results for patients with HLA-matched family or unrelated donors. However, even after fully myeloablative preparative regimens, mixed donor chimerism is a potential concern. We performed a retrospective chart review of 12 children who underwent allogeneic HSCT for WAS to report our experience. The median age at transplant was 10.5 months (range, 3 to 39). The median nucleated cell dose from the marrow was 4.55 × 10 9 /kg (range,.3 to 7.9). The median times to neutrophil and platelet engraftment were 19 days (range, 13 to 27) and 18.5 days (range, 12 to 31), respectively. The rate of overall survival was 92{\%} with median follow-up of 67 months (range, 3 to 146). Two patients developed grade IV acute graft-versus-host disease, and 1 died on day +99. Five of 12 patient's (42{\%}) had mixed donor chimerism (range, 12{\%} to 85{\%}) at day +180. None of the pretransplant patient parameters was predictive of mixed chimerism. Nonetheless, of these 5 patients, 2 had normalization of the platelet count despite the mixed chimerism, 2 had full donor chimerism after receiving a second transplant with the same donor, and 1 remains transfusion dependent awaiting a second transplant. Hence, even with a significant rate of mixed chimerism, HSCT provides substantial benefit to WAS patients, with excellent overall survival.",
keywords = "Hematopoietic cell transplant, Mixed chimerism, Primary immunodeficiency, Wiskott-Aldrich syndrome",
author = "Alexander Ngwube and Hanson, {I. Celine} and Jordan Orange and Rider, {Nicholas L.} and Filiz Seeborg and William Shearer and Lenora Noroski and Sarah Nicholas and Lisa Forbes and Kathryn Leung and Ghadir Sasa and Swati Naik and Meenakshi Hegde and Bilal Omer and Nabil Ahmed and Carl Allen and Stephen Gottschalk and Wu, {Meng Fen} and Hao Liu and Malcolm Brenner and Helen Heslop and Robert Krance and Caridad Martinez",
year = "2018",
month = "3",
day = "1",
doi = "10.1016/j.bbmt.2017.11.019",
language = "English (US)",
volume = "24",
pages = "537--541",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Outcomes after Allogeneic Transplant in Patients with Wiskott-Aldrich Syndrome

AU - Ngwube, Alexander

AU - Hanson, I. Celine

AU - Orange, Jordan

AU - Rider, Nicholas L.

AU - Seeborg, Filiz

AU - Shearer, William

AU - Noroski, Lenora

AU - Nicholas, Sarah

AU - Forbes, Lisa

AU - Leung, Kathryn

AU - Sasa, Ghadir

AU - Naik, Swati

AU - Hegde, Meenakshi

AU - Omer, Bilal

AU - Ahmed, Nabil

AU - Allen, Carl

AU - Gottschalk, Stephen

AU - Wu, Meng Fen

AU - Liu, Hao

AU - Brenner, Malcolm

AU - Heslop, Helen

AU - Krance, Robert

AU - Martinez, Caridad

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Wiskott-Aldrich syndrome (WAS) is a rare X-linked disorder characterized by a triad of immunodeficiency, eczema, and thrombocytopenia. Currently, hematopoietic stem cell transplantation (HSCT) is the most reliable curative treatment with excellent results for patients with HLA-matched family or unrelated donors. However, even after fully myeloablative preparative regimens, mixed donor chimerism is a potential concern. We performed a retrospective chart review of 12 children who underwent allogeneic HSCT for WAS to report our experience. The median age at transplant was 10.5 months (range, 3 to 39). The median nucleated cell dose from the marrow was 4.55 × 10 9 /kg (range,.3 to 7.9). The median times to neutrophil and platelet engraftment were 19 days (range, 13 to 27) and 18.5 days (range, 12 to 31), respectively. The rate of overall survival was 92% with median follow-up of 67 months (range, 3 to 146). Two patients developed grade IV acute graft-versus-host disease, and 1 died on day +99. Five of 12 patient's (42%) had mixed donor chimerism (range, 12% to 85%) at day +180. None of the pretransplant patient parameters was predictive of mixed chimerism. Nonetheless, of these 5 patients, 2 had normalization of the platelet count despite the mixed chimerism, 2 had full donor chimerism after receiving a second transplant with the same donor, and 1 remains transfusion dependent awaiting a second transplant. Hence, even with a significant rate of mixed chimerism, HSCT provides substantial benefit to WAS patients, with excellent overall survival.

AB - Wiskott-Aldrich syndrome (WAS) is a rare X-linked disorder characterized by a triad of immunodeficiency, eczema, and thrombocytopenia. Currently, hematopoietic stem cell transplantation (HSCT) is the most reliable curative treatment with excellent results for patients with HLA-matched family or unrelated donors. However, even after fully myeloablative preparative regimens, mixed donor chimerism is a potential concern. We performed a retrospective chart review of 12 children who underwent allogeneic HSCT for WAS to report our experience. The median age at transplant was 10.5 months (range, 3 to 39). The median nucleated cell dose from the marrow was 4.55 × 10 9 /kg (range,.3 to 7.9). The median times to neutrophil and platelet engraftment were 19 days (range, 13 to 27) and 18.5 days (range, 12 to 31), respectively. The rate of overall survival was 92% with median follow-up of 67 months (range, 3 to 146). Two patients developed grade IV acute graft-versus-host disease, and 1 died on day +99. Five of 12 patient's (42%) had mixed donor chimerism (range, 12% to 85%) at day +180. None of the pretransplant patient parameters was predictive of mixed chimerism. Nonetheless, of these 5 patients, 2 had normalization of the platelet count despite the mixed chimerism, 2 had full donor chimerism after receiving a second transplant with the same donor, and 1 remains transfusion dependent awaiting a second transplant. Hence, even with a significant rate of mixed chimerism, HSCT provides substantial benefit to WAS patients, with excellent overall survival.

KW - Hematopoietic cell transplant

KW - Mixed chimerism

KW - Primary immunodeficiency

KW - Wiskott-Aldrich syndrome

UR - http://www.scopus.com/inward/record.url?scp=85040556664&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040556664&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2017.11.019

DO - 10.1016/j.bbmt.2017.11.019

M3 - Article

VL - 24

SP - 537

EP - 541

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 3

ER -